Artificial Organs 2010: A Year in Review

Malchesky, Paul S.

doi:10.1111/j.1525-1594.2011.01225.x

Cited by 2 publications

(1 citation statement)

References 189 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The main goal of former therapeutic strategies, the functional enhancement of tissues as they are, is gradually being replaced by new strategies to regenerate tissues and organs (Bernardo et al 2011; Malchesky 2011). Two main strategies have been followed during the last two decades with respect to tissue regeneration.…”

Section: Introductionmentioning

confidence: 99%

In situ guided tissue regeneration in musculoskeletal diseases and aging

Jakob¹,

Ebert²,

Rudert³

et al. 2011

Cell Tissue Res

View full text Add to dashboard Cite

In situ guided tissue regeneration, also addressed as in situ tissue engineering or endogenous regeneration, has a great potential for population-wide “minimal invasive” applications. During the last two decades, tissue engineering has been developed with remarkable in vitro and preclinical success but still the number of applications in clinical routine is extremely small. Moreover, the vision of population-wide applications of ex vivo tissue engineered constructs based on cells, growth and differentiation factors and scaffolds, must probably be deemed unrealistic for economic and regulation-related issues. Hence, the progress made in this respect will be mostly applicable to a fraction of post-traumatic or post-surgery situations such as big tissue defects due to tumor manifestation. Minimally invasive procedures would probably qualify for a broader application and ideally would only require off the shelf standardized products without cells. Such products should mimic the microenvironment of regenerating tissues and make use of the endogenous tissue regeneration capacities. Functionally, the chemotaxis of regenerative cells, their amplification as a transient amplifying pool and their concerted differentiation and remodeling should be addressed. This is especially important because the main target populations for such applications are the elderly and diseased. The quality of regenerative cells is impaired in such organisms and high levels of inhibitors also interfere with regeneration and healing. In metabolic bone diseases like osteoporosis, it is already known that antagonists for inhibitors such as activin and sclerostin enhance bone formation. Implementing such strategies into applications for in situ guided tissue regeneration should greatly enhance the efficacy of tailored procedures in the future.

show abstract

Section: Introductionmentioning

confidence: 99%